CRISPR Therapeutics (CRSP) vs Scholar Rock (SRRK)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 9, 2026.
Summary
Scholar Rock (SRRK) has outperformed CRISPR Therapeutics (CRSP) over the past year, gaining 9.1% versus a loss of 34.3%. Over five years, SRRK leads with a +54.7% price change compared with -48.0% for CRSP. Scholar Rock is the larger company by market cap ($5.14 billion vs $4.88 billion), about 1.1 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | CRSP | SRRK |
|---|---|---|
| Share price | $50.44 | $42.20 |
| Market cap | $4.88B | $5.14B |
| 1-day change | -3.65% | 0.00% |
| YTD return | -3.81% | -4.20% |
| 1-year return | -34.31% | +9.07% |
| 5-year return | -48.00% | +54.75% |
| EPS (TTM) | $-4.74 | $-3.32 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | $3.51M | $0 |
| Revenue growth (YoY) | -90.59% | — |
| Net income (latest FY) | $-581.60M | $-377.94M |
| Operating margin | -18933.65% | — |
| Net margin | -16569.77% | — |
| 52-week high | $78.00 | $61.76 |
| 52-week low | $44.12 | $27.07 |
| Distance from 52-week high | -35.33% | -31.67% |
| Analyst consensus | buy | strong_buy |
| Avg. price target upside | +73.59% | +66.92% |
| Average volume | 1.62M | 1.53M |
| Shares outstanding | 96.69M | 121.79M |
| Employees | — | 289 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Biotechnology: Biological Products (No Diagnostic Substances) |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- SRRK has outperformed CRSP by 43.4 percentage points over the past year.
About CRISPR Therapeutics
CRSP stock →CRISPR Therapeutics AG, a gene editing company, focuses on developing gene-based medicines for serious human diseases using its Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/CRISPR-associated protein 9 (Cas9) platform. The company's CRISPR/Cas9 is a technology for gene editing which is the process of precisely altering specific sequences of genomic DNA.
Health Care · Biotechnology: Biological Products (No Diagnostic Substances)
About Scholar Rock
SRRK stock →Scholar Rock Holding Corporation, a biopharmaceutical company, focuses on improving the lives of children and adults with spinal muscular atrophy (SMA) and other rare, severe, and debilitating neuromuscular diseases. The company's novel understanding of the molecular mechanisms of growth factor activation within the transforming growth factor beta (TGFß) superfamily has enabled the development of a proprietary platform.
Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 289 employees
CRSP vs SRRK FAQ
Which is bigger, CRISPR Therapeutics or Scholar Rock?
Scholar Rock (SRRK) is larger, with a market capitalization of $5.14B compared with $4.88B for CRISPR Therapeutics (CRSP).
Which stock has performed better over the past year, CRSP or SRRK?
SRRK returned +9.07% over the past 12 months, compared with -34.31% for CRSP (price return, excluding dividends). Past performance does not predict future results.
Are CRISPR Therapeutics and Scholar Rock in the same industry?
Yes. Both are classified in the Biotechnology: Biological Products (No Diagnostic Substances) industry within the Health Care sector.